EBS Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Emergent BioSolutions (EBS)
Emergent BioSolutions shares dropped after the Company recorded a $191.3 million non-cash NARCAN impairment tied to naloxone competition and pricing pressure. Levi & Korsinsky is investigating potential securities law violations on behalf of EBS investors who lost money.
Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 million non-cash impairment on its NARCAN franchise, attributed to increased competition and pricing pressure in naloxone. If you suffered a loss on your Emergent BioSolutions investment, you are encouraged to click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
NARCAN Nasal Spray is Emergent's flagship commercial product. The naloxone category has drawn multiple generic and over-the-counter entrants, and the Company previously reported a 41% year-over-year decline in fourth-quarter NARCAN revenue, attributed to increased generic competition affecting both price and unit sales, alongside a nine-percentage-point decline in commercial-products gross margin to 16%.
